NEW YORK (GenomeWeb News) - The US Food and Drug Administration’s Oncologic Drugs Advisory Committee will meet Tuesday in Gaithersburg, Md., to discuss the validity of conducting retrospective clinical trials to define the genetic subpopulation for two metastatic colorectal cancer drugs, Amgen’s Vectibix and ImClone/Bristol-Myers Squibb Erbitux. 
 
The meeting could result in the FDA providing further clarity to pharmacogenomics companies on the agency’s position regarding Rx/Dx co-development.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.